Dendritic cells (DC) change their phenotype and functional properties during maturation. CD83 cell surface expression is induced on mature DC (mDC). In this study, we investigated intracellular CD83 localization and transport in human monocyte-derived DC. The enhanced level of CD83 cell surface expression in mDC resulted predominantly from increased protein synthesis, and in addition from regulated intracellular transport of CD83 protein. An internal pool of CD83 protein is present in immature DC (iDC). Although CD83 protein in iDC and in mDC was localized in the Golgi compartment and in recycling endosomes, only in mature cells did CD83 co-localize with MHC class II molecules in endocytic vesicles. CD83 cell surface expression on iDC was induced by inhibition of endocytosis. This result could be explained by CD83 cycling between endosomes and the cell surface in iDC. The mDC also rapidly internalized membrane-bound CD83 protein. Furthermore, a thiol protease inhibitor and specific cathepsin inhibitors impaired CD83 up-regulation in DC, indicating a role of endosomal proteases in the maturation-induced exposure of CD83 on the plasma membrane.
Introduction
Dendritic cells (DC) play a pivotal role as inducers and regulators of immune responses. After antigen uptake or as a consequence of inflammatory stimuli, DC undergo maturation events and acquire the ability to present antigenic peptides to T cells (1) . In their immature state, DC internalize and process antigens. During maturation they acquire the ability to activate naive T cells but loose their antigen-processing activity. Proinflammatory stimuli like tumor necrosis factor-alpha (TNFalpha) or mitogens such as LPS and double-stranded RNA like polyriboinosinic polyribocytodylic acid (poly I/C) induce maturation of DC. As a consequence of maturation, upregulation of MHC class I and class II molecules (2) , elevated levels of co-stimulatory molecules (CD80, CD86) and de novo exposure of CD83 on the cell surface are observed (1, 3) .
In humans, plasma membrane expression of the CD83 protein is widely used as a differentiation marker of mature DC (mDC). CD83 is also expressed on activated lymphocytes (4) and was recently detected on cytokine-activated neutrophils (5, 6) . The function of the CD83 polypeptide is not yet known. It has been speculated that CD83 influences DC-T cell interactions (7) (8) (9) (10) . In mice, CD83 in addition was detected on activated T cells and on thymic epithelial cells (11) (12) (13) . CD83 gene-deficient mice display a specific block in developing CD4 single-positive thymocytes, which could be mediated by the absence of CD83 on thymic epithelial cells (13) . A regulatory role of CD83 for positive selection of T h in the thymus was therefore suggested (13) . In humans, in contrast to mice, CD83 is found predominantly on thymic DC rather than on epithelial cells (4) . The biological role of the CD83 polypeptide expressed by human DC remains to be resolved.
CD83 was expressed after 1 or 2 days of stimulation on the cell surface of stimulated DC (8) . The mechanism leading to CD83 plasma membrane exposure is unclear. Immature human monocyte-derived DC (MoDC) express only low amounts of CD83 on their cell membrane. By intracellular staining and flow cytometry, an intracellular pool of CD83 protein has been detected in immature MoDC, which discriminates them from monocytes and macrophages (14) . In freshly isolated polymorphonuclear neutrophils, no intracellular pool of CD83 has been found (6) . Recent work documents the intracellular expression of CD83 protein in EBV-transformed B cells (15) .
In this study, we investigated intracellular localization and transport of CD83 protein in human MoDC. We show that immature MoDC contain an intracellular pool of CD83 protein in the Golgi complex and in endocytic vesicles. Membraneexposed CD83 protein of mDC is rapidly internalized and directed to endosomes. Maturation-induced CD83 cell surface display is regulated on the level of protein synthesis and by intracellular protein transport and is in addition triggered by endosomal/lysosomal proteases.
Methods
Reagents PE-labeled T6/RD1 (IgG1, Beckman-Coulter, Krefeld, Germany) reacts with CD1a, which is a marker for human DC. For detection of CD83, mAb HB15e (purified, IgG1, Caltag Laboratories, Burlingame, CA, USA) was used. For western blotting, CD83-specific mAb 1G11 (rat IgG1, Alexis, Lausen, Switzerland) and actin-specific mAb AC40 (Sigma, St Louis, MO, USA) were employed. HLA-DR was stained using mAb L243 hybridoma culture supernatant or mAb ISCR-3 culture supernatant, CD74, the invariant chain of MHC II, using Bu45 culture supernatant. CD80-specific mAb was from Pharmingen (IgG1, Mountain View, CA, USA). FITC-labeled F(ab)2 fragments of goat anti-mouse antibody, normal mouse serum and normal goat serum for blocking purposes were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Unlabeled IgG1, IgG2a and IgG2b and 7-aminoactinomycin D (7-AAD) were obtained from Sigma. PE-labeled IgG1 and PE-conjugated CD14-specific mAb were from Becton Dickinson (BD) (Mountain View, CA, USA).
Rabbit polyclonal antibodies for organelle labeling were directed against protein disulfide isomerase (PDI) in the endoplasmic reticulum (ER) (StressGen Biotechnologies Corp., Victoria, British Columbia, Canada), giantin in the Golgi compartment (a kind gift of Y. Misumi and Y. Ikehara, Fukuoka University, Fukuoka, Japan) and cellubrevin in early, recycling endosomes (a kind gift of R. Jahn, Gö ttingen, Germany). Lamp-2 was stained using a rat mAb from the Developmental Studies Hybridoma Bank at the University of Iowa (http://www.uiowa.edu/~dshbwww/abl93.html) and a Cy3-coupled goat anti-rat IgG (Jackson). For CD83 and MHC class II co-localization studies, a rabbit antiserum specific for the HLA-DR beta chain was employed (16) . Cy2-and Cy3-labeled F(ab)2 fragments of goat anti-mouse IgG as well as Cy2-and Cy3-labeled goat anti-rabbit IgG were purchased from Jackson.
Isolation and culture of peripheral blood monocytes
Monocytes were isolated from peripheral blood of healthy adults by density gradient centrifugation (Nycoprep, Nycomed, Oslo, Norway) as described previously (17) . The purity and viability of the cell preparation was evaluated by flow cytometric analysis via staining with anti-CD14-PE and 7-AAD and was consistently greater than 70% of viable monocytes. A total of 10 6 monocytes were cultured in 24-well plates with 1 ml very low endotoxin-RPMI 1640 (Biochrom, Berlin, Germany) supplemented with 10% heat-inactivated FCS, 1% antibiotics/antimycotics in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF) (500 U ml ÿ1 ; Novartis Pharma, Nü rnberg, Germany) and IL-4 (500 U ml ÿ1 ; Strathmann Biotech GmbH, Hannover, Germany). On day 2 of culture, 250 U ml ÿ1 IL-4 and 250 U ml ÿ1 GM-CSF were added to the medium, and on day 4 half of the medium was replaced and fresh cytokines were added.
Maturation of DC
In vitro-generated MoDC were stimulated with 10 ng ml ÿ1 TNF-alpha (R&D Systems Inc., Minneapolis, MN, USA) or 25 lg ml ÿ1 poly I/C (Sigma) for 2-24 h. When indicated, cells were treated with 1 lg ml ÿ1 cycloheximide (CHX) (Sigma), which blocks protein synthesis (18), 1 lg ml ÿ1 brefeldin A (BFA, Golgi Plug, BD Pharmingen, San Diego, CA, USA) influencing cis-and trans-Golgi transport and endocytosis (19, 20) , 3 lM Z-Val-Val-Nle-DMK (Bachem, Heidelberg, Germany), a specific cathepsin S (Cat S) inhibitor (21) , 100 nM Z-Phe-Tyr(tBu)-DMK (Bachem), a specific cathepsin L (Cat L) inhibitor (21), 20 nM concanamycin B (Con B, kind gift of J. Villadangos, Melbourne, Australia), which is active in endosomes and lysosomes (22) or 100 lM E64d (Bachem), an inhibitor of thiol proteases (23) 1 h before stimulation. In some experiments, cells were incubated with 10 lg ml ÿ1 cytochalasin D (Sigma) for the indicated time points.
Flow cytometric analysis
A total of 10 5 in vitro-generated cells were subjected to double-staining experiments for surface and intracellular staining with saponin and digitonin as described in detail elsewhere (24, 25) . At least 3 3 10 4 cells were analyzed with a FACSCalibur (BD).
For quantitative evaluation, 7-AAD staining excluded dead cells and the CD1a + populations were gated out manually using the CellQuest software (BD). The results are expressed in percentage of positive cells and mean fluorescence intensity (MFI) 6 SEM. Relative fluorescence indices (rFI) of the different structures were determined as follows: rFI = ½MFIðspecific antibodyÞ ÿ MFIðisotype controlÞ= MFIðisotype controlÞ:
Internalization of cell membrane molecules
At 4°C, cell membrane-exposed CD83, MHC II molecules and MHC II-associated invariant chain (CD74) were stained with specific antibodies (HB15e, L243 and Bu45, respectively). Unbound antibodies were removed and cells were allowed to metabolize at 37°C. After the indicated time periods, aliquots of the cells were transferred to 4°C and the remaining cell membrane-bound antibody was detected by FITC-labeled goat anti-mouse Ig and FACS analysis. The rFI values were calculated as shown above.
Western blotting
A total of 1 3 10 6 in vitro-generated cells were lysed using buffer containing 0.5% Nonidet P40. The samples were separated with 12% SDS gel and subjected to western blot analysis with 1 lg per 2 ml 1G11 as described in detail elsewhere (26) . Glycosidase treatment (PNGase F, New England Biolabs, Beverly, MA, USA) to remove N-linked carbohydrate structures was performed on lysates as prepared for western blotting. Proteins were de-glycosylated with PNGase F using the buffer recommended by the manufacturer. The reaction mixture was incubated for 16 h at 37°C. The samples were then separated on a 12% SDS gel and subjected to western blotting as described above.
Immunofluorescence staining and confocal microscopy A total of 10 5 immature or mature MoDC were allowed to adhere to poly (L) lysine-coated slides for 1 h and fixed using 70% methanol for 5 min at ÿ20°C. Slides were briefly air-dried and stored at ÿ70°C until staining. After thawing of the slides, they were double stained with CD83-specific mAb (10 lg ml ÿ1 ), MHC class II-specific L243 culture supernatant and antigiantin rabbit antiserum (1 : 300), anti-cellubrevin rabbit antiserum (1 : 300), anti-HLA-DR beta rabbit antiserum (1 : 300), Lamp-2-specific mAb (1 : 10) or the respective negative control for 1 h at room temperature in Tris-buffered saline (TBS) containing 2.5 mg ml ÿ1 intraglobin (Biotest, Dreieich, Germany). After two washes with TBS, the cells were incubated with Cy2-or Cy3-labeled goat anti-mouse antibody for 60 min at room temperature followed by two washes. Additional staining steps as described above were performed with another set of non-cross-reactive primary and secondary antibodies to achieve labeling of a second epitope. After staining, the samples were washed with TBS. Cover slips were mounted with Gel/Mount (Biomeda, Foster City, CA, USA) containing 50 mg ml ÿ1 1,4 diazobicyclo[2,2,2]octane (Sigma) and analyzed on a Zeiss LSM510 microscope (Carl Zeiss Jena GmbH, Jena, Germany) using the Zeiss LSM 510 Image Browser/Examination software.
Statistical analysis
Statistical analysis was performed using the non-parametric two-tailed Wilcoxon/Mann-Whitney test, which does not require normal distribution of the data and is thus best suited for relatively small data sets. Values of P < 0.05 were considered statistically significant.
Results

MoDC contain intracellular deposits of CD83 polypeptides
We generated DC from peripheral blood monocytes by stimulation with GM-CSF and IL-4. After 6 days of culture, 80-95% of cells expressed the DC marker CD1a. At first, we investigated the kinetics of CD83 cell surface expression after the treatment of immature MoDC with TNF-alpha. As early as 2 h after stimulation, CD83 was detected on the cell membrane of MoDC. After 12-24 h virtually all cells exposed CD83 at the cell surface. The following results were obtained with either poly I/C or with TNF-alpha treatment as indicated.
Intracellular protein transport mediates maturation-induced CD83 cell surface expression
Maturation-induced CD83 cell surface expression could be induced by de novo protein synthesis, since the CD83 gene is regulated by TNF-alpha (27) , which was used as a maturation stimulus. In addition, a restricted transport of the detected intracellular pool of CD83 molecules could control exit to the cell surface. Protein biosynthesis or vesicular transport was blocked by using inhibitors of protein synthesis (CHX) or transport (BFA), and Con B. CHX inhibits protein synthesis by blocking translation of messenger RNA on the ribosome. BFA induces a disassembly of the Golgi complex thereby blocking the secretory pathway at the level of the ER-Golgi juncture and at the level of the trans-Golgi network (TGN). Con B, an inhibitor of vacuolar ATPases, inhibits the acidification and thus raises the pH in MHC loading compartments.
We pre-treated immature MoDC for 1 h with inhibitors and subsequently stimulated the cells for 12 h with poly I/C and studied CD83 and HLA-DR cell surface expression by flow cytometry (Fig. 3 and Table 1 ). Numbers given in Fig. 3 display MFI values obtained from one representative experiment. Percent inhibition is displayed in Table 1 as mean and SEM from the number of experiments indicated in the legend for Table 1 . Maturation of DC led to de novo cell surface expression of CD83 and to elevated HLA-DR levels ( Fig. 3A  and B) . CD83 cell surface expression was reduced by 56% (Table 1 ) through inhibition of protein synthesis with CHX. Figure 3 (B and C) demonstrated reduction of relative MFI values from 81 to 45. Treatment of DC with BFA completely abrogated maturation-induced CD83 cell surface expression (Fig. 3D, left panel) and reduced maturation-induced surface display of HLA-DR molecules by 47% (Table 1 ). To exclude a toxic effect of BFA, we examined whether the BFA-induced down-regulation of CD83 expression was reversible. Washing of the cells after inhibition, but prior to stimulation, restored the maturation-induced up-regulation of CD83 (data not shown). Con B treatment also showed a strong inhibitory effect on CD83 and on HLA-DR cell membrane exposure after poly I/C treatment of DC (Fig. 3E ). In addition, we studied the effect of inhibitors of protein synthesis and transport on CD83 cell surface expression on MoDC stimulated with TNF-alpha instead of poly I/C with identical results compared with those presented in Fig. 3 (compare Table 1 ).
Incomplete inhibition of maturation-induced CD83 cell surface expression by CHX is consistent with an intracellular pool of preformed CD83 molecules in iDC. During maturation, CD83 molecules from this pool are transported to the cell membrane. Export of CD83 to the cell surface can be inhibited by transport inhibitors. We investigated the biosynthetic route of CD83 to the cell surface. Confocal microscopy analysis was applied to localize CD83-positive cellular compartments of iDC and mDC.
In immature MoDC, CD83 is localized in a Golgi compartment and in endosomes
We examined in which intracellular organelles CD83 protein is detected in immature and mature MoDC. Double stainings using CD83 mAb (green) and antiserum specific for giantin as a Golgi marker (red) revealed co-localization (yellow color) of CD83 with giantin in both immature (Fig. 4A-C) and mature ( Fig. 4G-I ) MoDC. CD83 and PDI did not co-localize neither in immature nor in mature MoDC (data not shown), implying that CD83 is not retained in the ER. In immature (Fig. 4D-F) as well as in mature MoDC (Fig. 4J-L) , CD83 also co-localized with cellubrevin, a v-SNARE protein, which is a constituent of recycling endosomes. Cellubrevin (red) is present in an endosomal compact structure around the nucleus and in small peripheral puncta in the cytoplasm, as described by Wilcke et al. (28) . Our results demonstrate the presence of CD83 in recycling compartments of iDC. DC maturation resulted in CD83 transport to the cellular membrane. In maturing cells, CD83 clearly co-localized with giantin and with cellubrevin. We observed the same staining pattern of CD83 protein at 30 min, 1, 2, 6, 12 and 24 h after stimulation (data not shown). This staining pattern is probably due to ongoing de novo biosynthesis during maturation, refilling CD83 deposits in the Golgi compartment and in endosomes. In addition Fig. 2A , lane 3, 7 or 11) were left untreated (lanes 1, 3 and 5) or were digested by PNGase F (lanes 2, 4 and 6). Subsequently, the lysates were separated by SDSP and western blotted for CD83.
to labeled intracellularly localized CD83, mDC display a pronounced staining of the plasma membrane (Fig. 4G, J and I, L), which was only marginally seen on iDC (Fig. 4A, C  and D, F) . The result in Fig. 4 shows that immature as well as mature MoDC contain CD83 deposits in the Golgi complex and in recycling endosomes, which upon maturation traffic to the cell membrane.
To examine endosomal localization of CD83, co-localization with MHC class II molecules was investigated. In iDC, MHC class II molecules are localized in endosomal/lysosomal compartments containing the lysosomal markers Lamp, Table  1 ) are shown (gray line: isotype control, black line: CD83 or HLA-DR, respectively). Experiments were performed as outlined for Fig. 3 . Mean percentages of inhibition 6 SEM were calculated as follows: 100 ÿ rFI (+inhibitor)/rFI (ÿinhibitor) 3 100. Data from six independent experiments (CHX and BFA) and from three experiments (Con B) are shown. Fig. 4 . In immature MoDC, CD83 is localized in the Golgi compartment and in recycling endosomes. Immature (A-F) and mature (G-L) MoDC were allowed to adhere to slides, fixed with methanol and first stained with CD83-specific mAb and goat anti-mouse IgG Cy2-labeled secondary reagent (green). Subsequently, giantin-specific antiserum (A-C and G-I) or cellubrevin-specific antiserum (D-F and J-L) and goat anti-rabbit IgG Cy3-labeled secondary antibody (red) were used as described in Methods. Scale bars represent 10 lm.
CD63 and b-hexosaminidase, which are negative for the early endosomal marker transferrin receptor. This compartment has been termed MHC class II-rich compartment (MIIC) (29) . Staining of iDC with mAb L243 specific for mature, peptideloaded MHC class II molecules (green) and with a cellubrevinspecific antiserum (Fig. 5A ) revealed partial co-localization of MHC class II molecules and cellubrevin (yellow) in only a small minority of cells (marked by asterisks). The absence of cellubrevin from most MIIC structures suggests that the CD83-positive endosomal structures are different from MIIC. Staining of iDC with CD83-specific antibody (green) and a rabbit serum specific for the beta chain of HLA-DR (red) (Fig. 5B) showed no co-localization and confirmed the result shown in Fig. 5(A) . Moreover, CD83 staining in iDC did not merge with Lamp-2-specific antibody labeling (Fig. 5E) . Thus, the intracellular pool of CD83 molecules in iDC is localized in an endosomal compartment positive for the v-SNARE protein cellubrevin and distinct from MIIC structures. In mDC, MHC class II molecules stained by L243 mAb (green) were found on the cell surface. No co-localization with cellubrevin (red) was observed (Fig. 5C ). In these cells (Fig. 4J-L) , CD83 (green) was expressed on the cell surface and was co-localizing with cellubrevin (red) intracellularly. In contrast to iDC, in mDC we observed co-localization (yellow) of CD83 (green) with MHC class II molecules (red), both on the cell surface and intracellularly (Fig. 5D ). CD83 co-stained with Lamp-2 ( Fig. 5F ), as expected from Lamp-positive MIIC structures. Neither in iDC nor in mDC were MHC II molecules detected in Golgi compartments, which was examined by staining of giantin (Fig. 5, G and H) . In iDC, we found CD83 protein in the Golgi complex and in recycling endosomes. CD83 does not co-localize with MHC class II molecules in iDC. In contrast, in mDC, CD83 and MHC class II molecules colocalize in an endosomal/lysosomal compartment defined by Lamp-2 expression, which is distinct from recycling endosomes.
Immature and mature MoDC internalize CD83 from the cell membrane
Rapid endocytosis and re-expression of low levels of CD83 molecules on the cell surface co-exist with a deposit of CD83 protein in recycling endosomes of iDC. If endocytosis of cell surface-expressed CD83 protein occurred on iDC, blockage of endocytosis should enhance the number of cell surface CD83 molecules and allow cell surface detection. Therefore, we treated immature MoDC with cytochalasin D, an inhibitor of endocytosis. Cytochalasin D depolymerizes and sequesters F-actin filaments and thus blocks endocytosis without affecting the exocytotic pathway (30) . After cytochalasin D treatment for 3 h, we observed CD83 cell surface expression in immature MoDC. As a control, the diluent dimethyl sulfoxide had no effect (Fig. 6A and B) . Twenty-four hours after cytochalasin D treatment, up to 30% of immature MoDC expressed CD83 on the cell surface. Elevation of CD83 expression upon cytochalasin D treatment was not due to DC maturation. Other markers of maturation like CD80 (Fig. 6C) and MHC I and MHC II antigens (data not shown) were not enhanced after cytochalasin D treatment of iDC. Inhibition of endocytosis promotes CD83 cell surface expression on iDC. A, B, E, G) and mature (C, D, F, H) MoDC were allowed to adhere to slides and were fixed with methanol. Cells were stained with MHC class II-specific L243 mAb and with goat anti-mouse Ig Cy2-labeled secondary reagent (A, C, green) followed by cellubrevin-specific antiserum and goat anti-rabbit Ig Cy3-labeled secondary antibody (red). In (B and D), staining was performed with CD83-specific mAb and goat anti-mouse Ig Cy2-labeled secondary reagent (B, D, green), and MHC class II-specific rabbit antiserum and goat anti-rabbit Ig Cy3-labeled secondary antibody (red). In (E and F) staining was performed with CD83-specific mAb and goat anti-mouse Ig Cy2-labeled secondary reagent (green), and a Lamp-2-specific rat mAb followed by a Cy3-coupled goat anti-rat IgG reagent (red). (G and H) show stainings with culture supernatant from HLA-DRspecific mAb ISCR-3 and goat anti-mouse Ig Cy2-labeled secondary reagent (green) and giantin-specific antiserum and goat antirabbit IgG Cy3-labeled secondary antibody (red). Scale bars represent 10 lM.
Membrane-bound CD83 protein was also rapidly internalized from mature MoDC. This is shown in Fig. 6(D, solid line) . Within 30 min at 37°C, CD83 membrane exposure on mDC was reduced by >50%. Figure 6 (E, left panel) shows corresponding FACS histograms. Results from five internalization experiments show a cell surface half-life of t 1/2 = 20 min for CD83 on mature MoDC. In comparison, MHC II surface expression was stable within 90 min (Fig. 6D, dashed line and Fig. 6E, middle  panel) , whereas 80% of membrane-exposed MHC II-associated invariant chain (Ii, CD74) was endocytosed in 10 min (Fig. 6D,  dotted line and Fig. 6E, right panel) . Within 30 min, CD83-bound antibodies were internalized and detected in endosomes by laser scanning microscopy (data not shown).
Inhibition of endocytosis of mature MoDC with cytochalasin D increased the cell surface half-life from t 1/2 = 20 min to t 1/2 = 90 min (Fig. 6F and G) . Delivery of CD83 to the cell membrane followed by internalization is important to maintain CD83 steady state levels on the cell surface of DC.
Proteases impact on CD83 cell surface expression
We showed that in mDC, CD83 protein co-localized in endocytic vesicles with MHC II heterodimers. Processing of MHC II molecules associated to Ii requires the activity of endosomal proteases, e.g. Cat S and Cat L (31). Since endocytic vesicles of mDC containing CD83 protein display proteolytic activity, we investigated whether lysosomal proteases impact on the maturation-induced up-regulation of CD83.
We employed a specific inhibitor of Cat S (Z-Val-Val-Nle-DMK), a Cat L inhibitor [Z-Phe-Tyr(tBu)-DMK] (25) and E64d, an inhibitor of thiol proteases, and examined maturationinduced up-regulation of CD83 surface expression. Immature MoDC were incubated with the inhibitors for 1 h and subsequently activated with TNF-alpha or poly I/C for 12 h. Figure 7 (A and B) shows that E64d almost completely inhibited CD83 surface expression (P < 0.001), while Cat S and Cat L inhibitors only slightly impaired (P < 0.05) maturation-induced display of CD83 cell surface molecules ( Fig. 7A and B) . Cat S and E64d thiol protease inhibitors significantly reduced maturation-induced HLA-DR up-regulation, whereas Cat L inhibitor had no remarkable effect (Fig. 7C) . In contrast to mDC, CD83 expression on iDC is not affected by protease inhibitors (data not shown). This result suggests a role of thiol proteases in the maturation-induced CD83 surface expression of DC.
Discussion
Maturation of human DC is a prerequisite for efficient antigen presentation to CD4 + T cells. De novo cell surface expression of CD83 is highly characteristic for mDC, albeit a function for CD83 has not been described. CD83 has been implicated in binding to ligands present on monocytes (7, 32) and on DC (9) . Recently, killing of human T lymphoblasts and activated DC in an allogeneic mixed lymphocyte reaction was shown to be enhanced by anti-CD83 antibody-dependent cytotoxicity of NK cells (33) . Cell surface expression appears to be implicated in the biological role of CD83.
We studied CD83 transport and intracellular localization during maturation of human MoDC. Intracellular staining of CD83 from in vitro-generated, detergent-permeabilized immature, CD83 cell surface-negative DC displayed CD83 intracellularly (14 and our data, not shown).
Western blot analysis of CD83 protein expressed by iDC revealed the presence of preformed CD83 protein with a m.w. of~38-40 kDa. During maturation of the cells in the presence of TNF-alpha or poly I/C, the m.w. gradually increased tõ 50 kDa. This reflects further glycosylation of CD83 protein during transport through the Golgi compartments. In addition, in TNF-alpha and in poly I/C-treated cells, a novel band with a m.w. of~32 kDa appeared, which is also the prominent band observed in CD83 cDNA-transfected COS cells. Removal of N-linked carbohydrates by PNGase F treatment of lysates from mature cells reduced CD83 forms with higher m.w. to 23 kDa. Therefore, the 32 kDa band presumably corresponds to a newly synthesized precursor form containing three N-linked glycans. The presence of the 32 kDa band in all lysates from TNF-alpha and from poly I/C-treated cells reflects ongoing de novo biosynthesis of this CD83 precursor molecule.
Hock et al. had shown that constitutive CD83 cell surface expression on human leukemia cell lines could be partially reduced by CHX (34) . Similar results were obtained in activated polymorphonuclear neutrophils with almost complete inhibition of CD83 surface expression upon treatment with CHX. However, in contrast to MoDC, freshly isolated polymorphonuclear neutrophils did not contain CD83 protein (6) . In immature PBMC-derived DC, Kruse et al. (8) found evidence for a CD83 RNA pool while these cells lack detectable CD83 protein by western blot analysis or immunofluorescence staining. In the absence of a CD83 protein depot in iDC, CD83 cell surface expression would depend on de novo protein synthesis, which should be completely blocked by CHX. Albert et al. detected intracellular CD83 expression in immature, surface CD83-negative DC. This contrasts to macrophages and CD83 surface-positive mDC (14) . We observed incomplete inhibition of maturation-induced CD83 cell surface expression of MoDC by CHX. De novo protein synthesis is not the only source for the maturation-induced CD83 cell surface expression of DC. Some preformed CD83 protein is also transported to the cell surface during maturation.
BFA induces two blocks in the vesicular transport pathway: one at the level of the ER-Golgi junction and the other at the TGN (19) . An inhibitory effect of BFA on antigen processing in late endosomes has also been reported (20) . BFA completely blocks delivery of CD83 derived from biosynthesis and from preformed molecules to the cell surface. Con B is a specific inhibitor of vacuolar (H+)-ATPases, a family of ATP-dependent proton pumps responsible for acidification of intracellular organelles in eukaryotic cells. In the presence of Con B, SDSstable dimer formation and export of class II molecules from the MHC II loading compartment is impaired (22) . Since Con B also inhibits CD83 cell surface expression of mDC, the MHC II loading compartment appears to be intersected by CD83 molecules on route to the cell surface.
Some of the employed transport inhibitors show even stronger impact on CD83 expression when compared with their impact on HLA-DR surface exposure. The iDC display substantial amounts of HLA-DR molecules on the cell surface. During maturation, the MFI value for HLA-DR roughly doubles. This increase in MFI can be inhibited by transport inhibitors.
By confocal scanning fluorescence microscopy, we localized CD83 in the Golgi complex and in vesicular structures of immature MoDC. The vesicular structures stained for cellubrevin, a constituent of early, recycling endosomes involved in membrane recycling (35) . Upon cell fractionation, CD83 was found enriched in an endosomal/lysosomal fraction from an EBV-transformed human B cell line (15) . Our data show that the endosomal localization can be found in iDC and mDC and that these vesicular structures probably belong to a recycling compartment. Based on our co-localization data obtained with CD83, MHC class II, Lamp-2 and cellubrevin, it can be hypothesized that preformed CD83 is intracellularly localized in the Golgi complex and in early recycling endosomes in iDC, while in mDC it is localized additionally in late endosomal compartments rich in MHC class II molecules (29) . After submission of the manuscript, Cao et al., 2005 reported about intracellular expression of CD83 in perinuclear regions (36) . These CD83 deposits correspond exactly to the endosomally localized CD83 protein described in this paper.
An intracellular CD83 pool in recycling endosomes of iDC may indicate endocytosis of (potentially ligand-bound) CD83 from the cell surface and subsequent recycling to the cell membrane. Cytochalasin D is a substance which sequesters actin filaments and thereby inhibits endocytosis without affecting protein recycling (30) . Cytochalasin D-induced CD83 cell surface expression on immature MoDC indicates CD83 endocytosis and recycling from the cell membrane. Via endocytosis, a putative CD83 ligand could enter DC, which could have impact on their functional role in immune regulation. Ligands of CD83, which yet have to be defined, could be T cell membrane components, which could facilitate DC-T cell interaction during antigen presentation. Our finding that cell surface-bound CD83 molecules from mDC are endocytosed with a half-life of 20 min supports this hypothesis.
Endosomes in DC are rich in proteases, e.g. Cat S and Cat L, which during antigen processing degrade the class IIassociated invariant chain and facilitate transport of peptideloaded class II molecules to the cell surface. Therefore, cell surface transport of MHC class II molecules can be blocked by inhibition of thiol proteases and by specific inhibitors of Cat S and Cat L. We investigated whether protease inhibitors would also influence CD83 cell surface expression. To limit the cytotoxicity of the inhibitors, CD83 surface expression was assessed after 12 h instead of 24 h in other experiments. DC matured for 12 h show moderate expression of CD83 on the cell surface. Despite the reduced maturation time, we observed an inhibitory effect of the protease inhibitors, which proved to be statistically significant in the Wilcoxon/MannWhitney rank sum test. Our finding that cathepsin inhibitors and E64d inhibit maturation-induced cell surface expression of CD83 suggests a role of thiol proteases for processing of CD83 transport. CD83 has also been described in other cell types than DC. Investigation of intracellular CD83 traffic and its recycling from the membrane of neutrophils, B cells and T cells may reveal additional insights in its potential target structures and function. Forschungsgemeinschaft 
